BASF and Royal DSM embroiled in animal feed patent suits
16-04-2020
Bayer buys BlueRock to build cell therapy expertise
09-08-2019
Sirada Wichitaphornkun / Shutterstock.com
Bayer has agreed to sell its animal health business to US-based Elanco Animal Health for $7.6 billion, as part of its strategic plan to focus on its core life sciences businesses.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Bayer, Elanco Animal Health, mergers and acquisitions, M&A, life sciences, animal health, Advantage, Coppertone, Dr Scholl’s
